Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome, everyone, to the afternoon session of the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Priyanka Grover, [Malcom Kuno] and [Jadel] Smith from the team.
Our next presenting company is Kiniksa and presenting on behalf of the company, we have CEO, Sanj Patel. (Operator Instructions) With that, Sanj, take it away.
Thanks, Anupam. It's good to be here again, albeit virtually, and thanks also to JPMorgan for hosting us today. I'm happy to highlight the commercial launch of our first approved product, ARCALYST, which is up to a very strong start. I'll also review our pipeline, which includes additional immune modulating assets, all of which have the potential for multiple follow-on indications.
There's a lot to cover, so let's get started. First, please note that I will be making forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |